New oral heart failure drug appears to be safe and well tolerated in 58-patient early clinical trial
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
An early clinical study shows that a new oral drug is safe and well tolerated in patients with chronic heart failure. The study, led by researchers at Karolinska Institutet, has been published in The Lancet.
Heart failure with reduced pumping capacity means that the heart struggles to pump blood effectively around the body. Despite current treatments, many patients' conditions worsen over time, and existing drugs that strengthen the heart's contractions can cause serious side effects, such as heart rhythm disturbances and effects on blood pressure.
In the study, researchers investigated a new drug, AC01, which targets the body's ghrelin receptor. Ghrelin is a hormone that influences metabolism and growth hormone release, and its receptor is also found in heart muscle. AC01 is intended to strengthen the heart's pumping ability through a different biological mechanism from traditional heart-stimulating drugs, thereby reducing the risk of side effects.
The study was a randomized, placebo-controlled Phase Ib/IIa trial involving 58 patients with stable, chronic heart failure with reduced pumping capacity. Participants received different doses of AC01 or placebo for either seven or 28 days. The main aim was to assess safety and tolerability.
The results show that the drug was well tolerated. No serious side effects linked to AC01 were reported. The researchers also found no signs of harmful effects on heart rhythm or blood pressure. Exploratory analyses additionally indicated signs of improved heart function, such as increased stroke volume and cardiac output.
"This is an early study with a limited number of patients, but the results suggest that AC01 can be administered safely to people with heart failure. The findings now justify further studies to investigate whether the signals of improved heart function that we have observed can lead to clinical benefit in larger and longer studies," says Lars Lund, first author and professor at the Department of Medicine, Solna, Karolinska Institutet, and senior consultant cardiologist at Karolinska University Hospital.
The study was conducted in collaboration with researchers and clinicians in several European countries.
Publication details
Lars H Lund et al, Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study, The Lancet (2026). DOI: 10.1016/s0140-6736(26)00904-9
Journal information: The Lancet
Key medical concepts
Clinical categories
CardiologyClinical pharmacology Provided by Karolinska Institutet Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New oral heart failure drug appears to be safe and well tolerated in 58-patient early clinical trial (2026, June 25) retrieved 25 June 2026 from https://medicalxpress.com/news/2026-06-oral-heart-failure-drug-safe.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.